Breast Cancer Trial, Recruiting NCT03144648 Sponsor: International Agency for Research on Cancer Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT03144648
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between 20 and 45 years old
  • Women who are within 3 years of age (older or younger) of the main study participant (the "case")
  • Women who have been living in the study area for the past 3 years
  • Women who have had at least one menstrual period in the past 12 months
  • Women who have been diagnosed with a primary breast cancer confirmed by a tissue sample test (this criterion applies only to the main study participants, called "cases")

Who may not be able to join:

  • Women currently receiving cancer treatments such as radiation therapy, chemotherapy, or anti-estrogen medications (except treatment for certain common skin cancers)
  • Women who are currently taking, or have taken in the past 6 months, any of the following medications: tamoxifen, raloxifene (Evista), toremifene (Fareston), exemestane (Aromasin), letrozole (Femara), anastrozole (Arimidex), or megestrol (Megace)
  • Women with long-term kidney failure
  • Women with a condition that would make communication during the study difficult (confirm with trial site)
  • Women who are currently pregnant or breastfeeding
  • Women who have previously been diagnosed with any cancer, except for certain common skin cancers
  • Women excluded for any other reason determined by the trial site (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sabina Rinaldi, PhD, International Agency for Research on Cancer, Lyon, France

Phone: +33 472738485

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
International Agency for Research on Cancer
Registry
ClinicalTrials.gov
Start date
12 October 2012
Est. completion
30 December 2025

Where this trial is recruiting

🇧🇷 Brazil 🇨🇱 Chile 🇨🇴 Colombia Costa Rica 🇲🇽 Mexico

Primary endpoints

breast cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov